Form 4: Intellia Therapeutics Executive Acquires Shares Through Restricted Stock Unit Grant

Michael P. Dube, VP, PAO and Interim PFO of Intellia Therapeutics, acquired 17,801 shares of common stock on July 1, 2024, through a restricted stock unit grant.

Summary

• On July 1, 2024, Michael P. Dube, VP, PAO and Interim PFO of Intellia Therapeutics, acquired 17,801 shares of common stock.
• The acquisition was a result of a grant of restricted stock units, each representing a contingent right to receive one share of Intellia common stock.
• Following the transaction, Dube beneficially owns 49,024 shares of Intellia Therapeutics common stock.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects an executive's increased stake in the company.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Executive compensation through stock grants is a common practice in the biotechnology industry to align the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in biotech, similar to companies like CRISPR Therapeutics and Editas Medicine.
• The size of the grant is likely determined by Intellia's compensation policies and benchmarked against peer companies.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates an executive's increased alignment with shareholder interests.

Key Dates